Biotech Values

[biomaven0]

>>Non-invasive biomarkers of liver fibrosis

On the Fibrogen call, they said that biopsies in HBV infection (with concomitant treatment of HBV) proved too noisy for them to conclude anything much (this is a small Hong Kong based open label trial).

They said they they were going to bring the liver program back to the US and look at two biomarkers in patients with more advanced liver fibrosis - hepatic venous pressure gradients and something called HepQuant, "a dual stable isotope labeled collate product, that actually simultaneously measures liver function and liver blood flow." Also going to look at high-resolution MRI and MRS.

Peter